Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ELVN 
Enliven Therapeutics Inc. (ELVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: ELVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $41.25
1 Year Target Price $41.25
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -56.32% | Avg. Invested days 24 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.18B USD | Price to earnings Ratio - | 1Y Target Price 41.25 |
Price to earnings Ratio - | 1Y Target Price 41.25 | ||
Volume (30-day avg) 8 | Beta 1.04 | 52 Weeks Range 13.30 - 29.79 | Updated Date 11/4/2025 |
52 Weeks Range 13.30 - 29.79 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.99 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.5007 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.19% | Return on Equity (TTM) -25.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 690049096 | Price to Sales(TTM) - |
Enterprise Value 690049096 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.28 | Shares Outstanding 59235547 | Shares Floating 36383658 |
Shares Outstanding 59235547 | Shares Floating 36383658 | ||
Percent Insiders 8.23 | Percent Institutions 104.43 |
Upturn AI SWOT
Enliven Therapeutics Inc.
Company Overview
History and Background
Enliven Therapeutics, Inc. is a clinical-stage precision oncology company focused on discovering and developing next-generation therapies to address unmet needs for cancer patients. Founded in 2018, Enliven's pipeline is designed to address a broad range of driver mutations. The company is headquartered in Boulder, Colorado.
Core Business Areas
- Oncology Drug Development: Enliven focuses on discovering and developing small molecule kinase inhibitors for cancer treatment. This includes research, preclinical development, and clinical trials.
Leadership and Structure
Sam Blackman is the CEO. The organizational structure includes research, development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- ELVN-3231 (FGFR Inhibitor): ELVN-3231 is an investigational, selective, brain-penetrant FGFR inhibitor for FGFR2-altered solid tumors, including cholangiocarcinoma. It is currently in Phase 1 clinical trials. Market share is currently 0 as it is not yet on the market. Competitors include Incyte (PEMAZYRE) and Taiho Oncology (Lytgobi).
- ELVN-3106 (HER2 Inhibitor): ELVN-3106 is an investigational, selective, brain-penetrant HER2 inhibitor designed to target tumors with HER2 mutations and HER2 exon 20 insertion mutations. It is currently in Phase 1 clinical trials. Market share is currently 0 as it is not yet on the market. Competitors include Daiichi Sankyo/AstraZeneca (Enhertu) and Puma Biotechnology (Nerlynx).
Market Dynamics
Industry Overview
The oncology therapeutics market is a large and rapidly growing market driven by aging populations, increasing cancer incidence, and advancements in targeted therapies and immunotherapies. Precision oncology is a key area of growth.
Positioning
Enliven Therapeutics focuses on developing next-generation kinase inhibitors, aiming to overcome resistance mechanisms and improve outcomes for cancer patients. They are positioned as an innovator in precision oncology, specifically targeting FGFR and HER2 alterations.
Total Addressable Market (TAM)
The total addressable market for FGFR and HER2 inhibitors is significant and growing, estimated to be in the billions of dollars annually. Enliven is positioned to capture a portion of this market with its novel therapies, assuming successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel pipeline of selective kinase inhibitors
- Focus on precision oncology and unmet needs
- Experienced management team
- Strong financial backing
Weaknesses
- Early-stage clinical development (high risk)
- Dependence on successful clinical trial outcomes
- Potential for competition from established players
- Limited commercial infrastructure
Opportunities
- Potential for breakthrough therapies in targeted indications
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to address additional targets
- Regulatory fast-track designations
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing similar therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- INCY
- AZN
- PBYI
Competitive Landscape
Enliven faces competition from larger, more established pharmaceutical companies with approved products and extensive resources. However, Enliven's selective kinase inhibitors and focus on brain-penetrant therapies may offer a competitive advantage in specific patient populations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is based on preclinical and early clinical data. The company is experiencing growth in its R&D pipeline and clinical trial activity.
Future Projections: Future growth projections depend on successful completion of clinical trials and regulatory approval for ELVN-3231 and ELVN-3106.
Recent Initiatives: Recent initiatives include progressing ELVN-3231 and ELVN-3106 through Phase 1 clinical trials, presenting clinical trial data at medical conferences, and expanding the research pipeline.
Summary
Enliven Therapeutics is an early-stage precision oncology company with a promising pipeline targeting FGFR and HER2 alterations. While the company faces significant clinical and regulatory risks, its innovative approach and strong financial backing offer potential for future growth. Successful clinical trials are critical for realizing its potential. It needs to watch out for competitors that have the resources to move faster.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Enliven Therapeutics Investor Relations
- SEC Filings
- Industry Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enliven Therapeutics Inc.
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2020-03-12 | Co-Founder, CEO, Secretary & Director Mr. Samuel S. Kintz M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 63 | |
Full time employees 63 | |||
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.